GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q3 FY23 results · Oct–Dec 2022
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹802.30 crore (down 1.7% from Q3 FY22) and net profit of ₹164.56 crore (up 9.5% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 802.30 | 815.92 | −1.7% | 916.87 | −12.5% |
| Other income | 23.42 | 10.32 | +126.9% | 21.97 | +6.6% |
| Total income | 825.72 | 826.24 | −0.1% | 938.84 | −12.0% |
| Profit before tax | 224.25 | 171.76 | +30.6% | 262.15 | −14.5% |
| Net profit for the period | 164.56 | 150.35 | +9.5% | 193.42 | −14.9% |
| EPS, basic (₹) | 9.71 | 8.88 | +9.4% | 11.42 | −15.0% |
| Net margin (%) | 20.5 | 18.4 | 21.1 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 799.11 | 807.98 | −1.1% | 905.61 | −11.8% |
| Other income | 23.60 | 10.50 | +124.8% | 22.16 | +6.5% |
| Total income | 822.71 | 818.48 | +0.5% | 927.77 | −11.3% |
| Profit before tax | 223.53 | 170.79 | +30.9% | 262.33 | −14.8% |
| Net profit for the period | 164.03 | 149.63 | +9.6% | 193.56 | −15.3% |
| EPS, basic (₹) | 9.68 | 8.83 | +9.6% | 11.42 | −15.2% |
| Net margin (%) | 20.5 | 18.5 | 21.4 |
Consolidated
- Filed with BSE
- 08 Feb 2023, 11:19 IST
- Board meeting
- 07 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Feb 2023, 11:19 IST
- Board meeting
- 07 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE